Hikma Pharmaceuticals Plc Hikma appoints Chief Transformation Officer
June 04 2018 - 4:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
04 June 2018
London, 4 June 2018 - Hikma Pharmaceuticals PLC (Hikma, Group)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's /
BB+ S&P, both stable) announces the appointment of Henriette
Nielsen to the newly created role of Chief Transformation Officer.
In this role, Henriette will be responsible for leading a number of
initiatives across Hikma's global operations to improve operational
efficiency and ensure that Hikma achieves its strategic objectives.
She will join Hikma's Executive Committee and will report directly
to Siggi Olafsson, Hikma's Chief Executive Officer. Her appointment
is effective from 4 June 2018.
Siggi Olafsson said, "Henriette brings extensive experience in
pharmaceutical operations and transformation projects and has a
strong track record of formulating and executing global strategic
initiatives and developing multi-functional work plans. She brings
an entrepreneurial attitude that I am confident will fit well
within the Hikma culture."
Henriette joins Hikma from Teva Pharmaceuticals USA, where she
was most recently Senior Vice President, Chief Transformation
Officer, Global Marketing & Portfolio. Her previous experience
includes founder of System Matters, a healthcare and impact
investing consultancy, and General Counsel and EVP at Actavis
Group. She also held senior roles at Alpharma, Netdoktor and
Kromann Reumert.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and Director +44 (0)20 7399 2760/ +44 7776
of Investor Relations 477050
Virginia Spring +44 (0)20 3892 4389/ +44 7973
Investor Relations Manager 679502
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASSWFDFFASEIM
(END) Dow Jones Newswires
June 04, 2018 04:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024